duchenne Ireland - Research

By: Duchenne Ireland  05/12/2011
Keywords: Clinical Trials

September 2011

Genzyme has developed this Programme Update as a way to communicate about

ataluren and as part of our ongoing commitment in keeping the DBMD community

informed.

-----------------------------------------------------------------------------------------------

As reported in our June Programme Update, Genzyme has been actively exploring

various options in our efforts to determine appropriate next steps for the nmDBMD

programme. While we have been very pleased with our long-standing relationship

with PTC, as a result of our recent portfolio alignment process, we would like to

inform the community that Genzyme has decided to restructure our relationship with

PTC for the ataluren nmDBMD programme. We will, however, retain an option to

reengage the collaboration for non-nmDBMD indications, which reflects our belief in

the potential of this approach for the treatment of nonsense mutation genetic

disorders.

Also in our June Programme Update, Genzyme informed the nmDBMD community

that we initiated start up activities for a follow-on clinical study for patients who

participated in earlier ataluren nmDBMD clinical trials.  Moving forward, PTC now has

full, global responsibility for the clinical, regulatory and commercial strategy of

ataluren in nmDBMD. Genzyme will work closely with PTC to ensure an efficient

transition of all DBMD related activities to PTC. Questions relating to the follow-on

safety study follow-on clinical study for patients who participated in earlier ataluren

nmDBMD clinical trials should be directed to PTC. 

If you have any questions relating to this announcement or the follow-on safety study,

we would kindly ask that you forward these directly to PTC who are best placed to

address them. PTC can be contacted either by e-mail at

or by telephone +1 866 282-5873.

Genzyme is deeply impressed by the unwavering dedication, support and

collaboration within the community on the behalf of families affected by DBMD,

particularly the boys living with this disease. We have greatly appreciated the

community’s patience and engagement in ongoing dialogue during our involvement

with the ataluren nmDBMD programme. Even though Genzyme will no longer be

involved with ataluren in nmDBMD, we would like to assure you that we remain

committed to the neuromuscular patient community and will continue to look for

innovative, transformative therapies for those with unmet medical needs.

Keywords: Clinical Trials

Contact Duchenne Ireland

Email

Print this page

Share

Other products and services from Duchenne Ireland

05/12/2011

duchenne Ireland - News

Three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, including the first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient following systemic administration of a drug.


05/12/2011

duchenne Ireland - Events

The cycle arranged to fund research into Duchenne Muscular Dystrophy will take the participants from the National University of Ireland in Galway to Maynooth. Cyclists accross Ireland are getting ready for the inaugural "Tour Duchenne" charity cycling event on Saturday 12th and Sunday 13th of September 2009. Be on the look out for our yellow "Tour Duchenne 2009" cycling jerseys.


05/12/2011

duchenne Ireland - Collaboration

This project would not be in place at all if it was not for the dedicated work of Professor Steve Wilton and Professor Sue Fletcher from the University of Western Australia who have consistently progressed therapies for Duchenne boys over the past number of years since Exon Skipping showed initial therapeutic potential.


05/12/2011

duchenne Ireland - Fundraising

Funding for Duchenne Ireland research is generated from charity events such as this weekend’s Tour Duchenne 2010, taking place at 9am at the Aquarium, Strand Road, Bray.Tour Duchenne Is Duchenne Ireland’s annual charity cycle to raise funds for Duchenne Muscular Dystrophy research.